Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents

Biochemical Pharmacology

Volumn 81, Issue 5, 2011, Pages 563-568

  Yonezawa, Atsushi ^a   Inui, Ken Ichi ^a,b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; Copper transporter Ctr1; Drug transporter; Pharmacokinetics; Renal handling

Indexed keywords

CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; NEDAPLATIN; ORGANIC CATION TRANSPORTER 1; OXALIPLATIN; PLATINUM; PROTEIN MATE2; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG STRUCTURE; ENZYME SPECIFICITY; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE SPECIFICITY;

EID: 79551489546     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.11.016     Document Type: Note

References (60)

1. F.E. de Jongh, R.N. van Veen, S.J. Veltman, R. de Wit, M.E. van der Burg, and M.J. van den Bent Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients Br J Cancer 88 2003 1199 1206
2. D.C. Dobyan, J. Levi, C. Jacobs, J. Kosek, and M.W. Weiner Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations J Pharmacol Exp Ther 213 1980 551 556
3. R. Thadhani, M. Pascual, and J.V. Bonventre Acute renal failure N Engl J Med 334 1996 1448 1460
4. M.D. Hall, M. Okabe, D.W. Shen, X.J. Liang, and M.M. Gottesman The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy Annu Rev Pharmacol Toxicol 48 2008 495 535
5. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat Rev Drug Discov 4 2005 307 320
6. D. Grundemann, V. Gorboulev, S. Gambaryan, M. Veyhl, and H. Koepsell Drug excretion mediated by a new prototype of polyspecific transporter Nature 372 1994 549 552
7. V. Gorboulev, J.C. Ulzheimer, A. Akhoundova, I. Ulzheimer-Teuber, U. Karbach, and S. Quester Cloning and characterization of two human polyspecific organic cation transporters DNA Cell Biol 16 1997 871 881
8. M. Okuda, H. Saito, Y. Urakami, M. Takano, and K. Inui cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2 Biochem Biophys Res Commun 224 1996 500 507
9. H. Motohashi, Y. Sakurai, H. Saito, S. Masuda, Y. Urakami, and M. Goto Gene expression levels and immunolocalization of organic ion transporters in the human kidney J Am Soc Nephrol 13 2002 866 874
10. J.W. Jonker, E. Wagenaar, S. Van Eijl, and A.H. Schinkel Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations Mol Cell Biol 23 2003 7902 7908
11. R. Kekuda, P.D. Prasad, X. Wu, H. Wang, Y.J. Fei, and F.H. Leibach Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta J Biol Chem 273 1998 15971 15979
12. K. Inui, S. Masuda, and H. Saito Cellular and molecular aspects of drug transport in the kidney Kidney Int 58 2000 944 958
13. H. Koepsell, K. Lips, and C. Volk Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications Pharm Res 24 2007 1227 1251
14. M. Otsuka, T. Matsumoto, R. Morimoto, S. Arioka, H. Omote, and Y. Moriyama A human transporter protein that mediates the final excretion step for toxic organic cations Proc Natl Acad Sci USA 102 2005 17923 17928
15. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2 J Am Soc Nephrol 17 2006 2127 2135
16. +/organic cation antiporter MATE1 Am J Physiol Renal Physiol 292 2007 F593 F598
17. M. Tsuda, T. Terada, T. Mizuno, T. Katsura, J. Shimakura, and K. Inui Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin Mol Pharmacol 75 2009 1280 1286
18. S. Watanabe, M. Tsuda, T. Terada, T. Katsura, and K. Inui Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice J Pharmacol Exp Ther 334 2010 651 656
19. +/organic cation antiporters (MATE/SLC47A) Biochem Pharmacol 75 2008 1689 1696
20. T. Sato, S. Masuda, A. Yonezawa, Y. Tanihara, T. Katsura, and K. Inui Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1 Biochem Pharmacol 76 2008 894 903
21. A. Yonezawa, S. Masuda, K. Nishihara, I. Yano, T. Katsura, and K. Inui Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat Biochem Pharmacol 70 2005 1823 1831
22. G. Ciarimboli, T. Ludwig, D. Lang, H. Pavenstadt, H. Koepsell, and H.J. Piechota Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2 Am J Pathol 167 2005 1477 1484
23. A. Yonezawa, S. Masuda, S. Yokoo, T. Katsura, and K. Inui Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family) J Pharmacol Exp Ther 319 2006 879 886
24. H. Burger, A. Zoumaro-Djayoon, A.W. Boersma, J. Helleman, E.M. Berns, and R.H. Mathijssen Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) Br J Pharmacol 159 2010 898 908
25. S. Yokoo, A. Yonezawa, S. Masuda, A. Fukatsu, T. Katsura, and K. Inui Differential contribution of organic cation transporters OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 74 2007 477 487
26. K.K. Filipski, W.J. Loos, J. Verweij, and A. Sparreboom Interaction of Cisplatin with the human organic cation transporter 2 Clin Cancer Res 14 2008 3875 3880
27. K.K. Filipski, R.H. Mathijssen, T.S. Mikkelsen, A.H. Schinkel, and A. Sparreboom Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity Clin Pharmacol Ther 86 2009 396 402
28. Y. Tanihara, S. Masuda, T. Katsura, and K. Inui Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2 Biochem Pharmacol 78 2009 1263 1271
29. G. Ciarimboli, D. Deuster, A. Knief, M. Sperling, M. Holtkamp, and B. Edemir Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions Am J Pathol 176 2010 1169 1180
30. O. Briz, M.A. Serrano, N. Rebollo, B. Hagenbuch, P.J. Meier, and H. Koepsell Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells Mol Pharmacol 61 2002 853 860
31. S. Zhang, K.S. Lovejoy, J.E. Shima, L.L. Lagpacan, Y. Shu, and A. Lapuk Organic cation transporters are determinants of oxaliplatin cytotoxicity Cancer Res 66 2006 8847 8857
32. A.F. LeRoy, R.J. Lutz, R.L. Dedrick, C.L. Litterst, and A.M. Guarino Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu Cancer Treat Rep 63 1979 59 71
33. R.J. Knox, F. Friedlos, D.A. Lydall, and J.J. Roberts Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis- diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA Cancer Res 46 1986 1972 1979
34. E. Jerremalm, M. Hedeland, I. Wallin, U. Bondesson, and H. Ehrsson Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex Pharm Res 21 2004 891 894
35. F. Elferink, W.J. van der Vijgh, I. Klein, and H.M. Pinedo Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding Clin Chem 32 1986 641 645
36. H. Ehrsson, I. Wallin, G. Ciarimboli, and E. Schlatter Cimetidine as an organic cation transporter antagonist Am J Pathol 177 2010 1573 1574
37. M. Takano, K. Inui, T. Okano, H. Saito, and R. Hori Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles Biochim Biophys Acta 773 1984 113 124
38. B. Zhou Gitschier J. hCTR1: a human gene for copper uptake identified by complementation in yeast Proc Natl Acad Sci USA 94 1997 7481 7486
39. N. Pabla, R.F. Murphy, K. Liu, and Z. Dong The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity Am J Physiol Renal Physiol 296 2009 F505 F511
40. S. Ishida, J. Lee, D.J. Thiele, and I. Herskowitz Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals Proc Natl Acad Sci USA 99 2002 14298 14302
41. C.A. Larson, B.G. Blair, R. Safaei, and S.B. Howell The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs Mol Pharmacol 75 2009 324 330
42. I.S. Song, N. Savaraj, Z.H. Siddik, P. Liu, Y. Wei, and C.J. Wu Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells Mol Cancer Ther 3 2004 1543 1549
43. S.G. Aller, and V.M. Unger Projection structure of the human copper transporter CTR1 at 6-A resolution reveals a compact trimer with a novel channel-like architecture Proc Natl Acad Sci USA 103 2006 3627 3632
44. A.K. Holzer, K. Katano, L.W. Klomp, and S.B. Howell Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells Clin Cancer Res 10 2004 6744 6749
45. C.L. Litterst, T.E. Gram, R.L. Dedrick, A.F. Leroy, and A.M. Guarino Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs Cancer Res 36 1976 2340 2344
46. M. Okuda, K. Tsuda, K. Masaki, Y. Hashimoto, and K. Inui Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells: role of basolateral membrane transport Toxicol Lett 106 1999 229 235
47. T. Ludwig, C. Riethmuller, M. Gekle, G. Schwerdt, and H. Oberleithner Nephrotoxicity of platinum complexes is related to basolateral organic cation transport Kidney Int 66 2004 196 202
48. J.J. Gullo, C.L. Litterst, P.J. Maguire, B.I. Sikic, D.F. Hoth, and P.V. Woolley Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion Cancer Chemother Pharmacol 5 1980 21 26
49. P.E. Gormley, J.M. Bull, A.F. LeRoy, and R. Cysyk Kinetics of cis-dichlorodiammineplatinum Clin Pharmacol Ther 25 1979 351 357
50. C. Jacobs, S.M. Kalman, M. Tretton, and M.W. Weiner Renal handling of cis-diamminedichloroplatinum(II) Cancer Treat Rep 64 1980 1223 1226
51. P.T. Daley-Yates, and D.C. McBrien The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid Biochem Pharmacol 31 1982 2243 2246
52. Z.H. Siddik, D.R. Newell, F.E. Boxall, and K.R. Harrap The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats Biochem Pharmacol 36 1987 1925 1932
53. B.T. Sorensen, A. Stromgren, P. Jakobsen, J.T. Nielsen, L.S. Andersen, and A. Jakobsen Renal handling of carboplatin Cancer Chemother Pharmacol 30 1992 317 320
54. S.J. Harland, D.R. Newell, Z.H. Siddik, R. Chadwick, A.H. Calvert, and K.R. Harrap Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function Cancer Res 44 1984 1693 1697
55. W. Kern, J. Braess, B. Bottger, C.C. Kaufmann, W. Hiddemann, and E. Schleyer Oxaliplatin pharmacokinetics during a four-hour infusion Clin Cancer Res 5 1999 761 765
56. C.H. Takimoto, M.A. Graham, G. Lockwood, C.M. Ng, A. Goetz, and D. Greenslade Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function Clin Cancer Res 13 2007 4832 4839
57. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am J Med Sci 334 2007 115 124
58. T. Nakamura, A. Yonezawa, S. Hashimoto, T. Katsura, and K. Inui Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity Biochem Pharmacol 80 2010 1762 1767
59. M. Tsuda, T. Terada, M. Ueba, T. Sato, S. Masuda, and T. Katsura Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells J Pharmacol Exp Ther 329 2009 185 191
60. S. Matsushima, K. Maeda, K. Inoue, K.Y. Ohta, H. Yuasa, and T. Kondo The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine Drug Metab Dispos 37 2009 555 559